Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Trends in the Epidemiology of Breast Cancer Are Encouraging

November 1, 1998
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 11
Volume 7
Issue 11

WASHINGTON--Though the number of new breast cancer diagnoses has risen steadily in the United States for several years--now reaching approximately 200,000 a year--epidemiologic analysis reveals a number of hopeful trends, said Robert A Smith, PhD, senior director of detection programs for the American Cancer Society, Atlanta.

WASHINGTON--Though the number of new breast cancer diagnoses has risen steadily in the United States for several years--now reaching approximately 200,000 a year--epidemiologic analysis reveals a number of hopeful trends, said Robert A Smith, PhD, senior director of detection programs for the American Cancer Society, Atlanta.

Speaking at the American College of Radiology’s 28th National Conference on Breast Cancer, he noted that continuing numerical increase in this age-specific disease does not reflect an increasing age-adjusted incidence but, rather, the doubling of the female population aged 30 to 80 that will occur between 1960 and 2020.

Compared with the situation 15 years ago, today’s cancers are found at smaller sizes and earlier stages, he said. In 1994, 54% percent of breast cancers were diagnosed in situ or at stage 1, compared with 31% in 1983. Ductal carcinoma in situ (DCIS), technically a "precancerous" condition, Dr. Smith said, now ranks as the fourth most common cancer diagnosis in American women.

Survival rates at 5, 10, and 15 years have increased steadily, which, because of earlier diagnosis, represent a real lengthening of life. And recent years have seen the first mortality drop among breast cancer patients in 50 years, he noted. Between 1991 and 1995 alone, breast cancer mortality declined 6%, initially in young and white women and now also among minorities.

Despite a widespread impression to the contrary, Dr. Smith continued, many of the most widely known modifiable risk factors for breast cancer--including early menarche, late menopause, postmenopausal obesity, and hormone replacement therapy--do not raise incidence very much, except in women at very high genetic risk.

The relative risks of these factors may appear impressive, Dr. Smith said, but the absolute risk of breast cancer--which he defined as the underlying probability of getting the disease over a specific time span--is not great even into late middle age for women without a positive family history.

For the 10 years between ages 40 and 50, an average woman has a 1.5% chance of getting breast cancer, which rises to 2.3% in the years between ages 50 and 60.

Modifiable factors that do have significant protective effects in average-risk women are early age at first birth, lactation, and physical activity. But "reproductive decisions are made in a social context," he noted, in which considerations of breast cancer risk generally play a very small role, and the "protective role of childbirth is gone by age 30."

Regular, vigorous exercise can have up to a 60% protective effect on women under age 40, he added.

For women from high-risk families, however, some risk factors act differently than in the general population. Early birth, for example, increases rather than reduces risk for these women.

Modifiable Risk Factors

Modifiable factors that increase risk include alcohol consumption and use of hormone replacement therapy after menopause. Consuming between 30 and 60 grams of alcohol a day--about 2.3 to 4.5 beers, 2.8 to 5.6 glasses of wine, or 2 to 4 shots of whisky--significantly increases risk. Hormone replacement therapy appears to increase risk somewhat for present users but to have no long-term effect after use stops.

The best predictors of breast cancer, Dr. Smith said, are family history, personal history of breast cancer, and biopsy-confirmed benign tumors. The "best advice," he said, is to reduce alcohol, maintain a desirable weight, and exercise regularly.

Articles in this issue

Vinorelbine/Cisplatin Improves Survival In Advanced NSCLC
Centers Selected for STAR, Study of Tamoxifen and Raloxifene
HDC/PBSC for Advanced Breast Cancer Debated
New Programs Aim to Improve Home Care Services
Breast Cancer Patients Sought for Study of Premature Menopause
Study Update Shows Improved Survival With Anastrozole
New Colon Cancer Mouse Model First to Mimic Human Disease
Best Use of Breast Cancer Genetics Presents Clinical Challenge
Families Share Pleasure and Pain at The March
Panel Lists 13 Areas for Emphasis in NCI Breast Cancer Research
NCI Urged to Seize Opportunity for Prostate Cancer Research
Trends in the Epidemiology of Breast Cancer Are Encouraging
New Technology Allows Intravenous Injection of Busulfan
Tracking Case Rate Contracts for Stem Cell Transplants
Brachytherapy for Prostate Cancer Not Just Another Gimmick
Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Advertisement

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

3 Things You Should Know About Single-Agent ADCs in TNBC Treatment

ONCOLOGY Staff
October 29th 2025
Article

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Notably, improvements in both the ESR1 mutated population and the intent-to-treat population, including ESR1 wild type, were announced, and data will be presented at an upcoming scientific meeting.

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Neil M. Iyengar, MD
October 24th 2025
Article

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Dato-DXd May Be Next SOC in First-Line TNBC

Dato-DXd May Be Next SOC in First-Line TNBC

Kristi Rosa
October 20th 2025
Article

Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.


Policies aimed at improving health coverage and financial assistance may help improve treatment affordability to ensure more equitable survival.

Data Show Growing Trend in Insurance/Racial OS Disparities in Breast Cancer

Roman Fabbricatore
October 20th 2025
Article

Policies aimed at improving health coverage and financial assistance may help improve treatment affordability to ensure more equitable survival.

Related Content
Advertisement

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

3 Things You Should Know About Single-Agent ADCs in TNBC Treatment

ONCOLOGY Staff
October 29th 2025
Article

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Notably, improvements in both the ESR1 mutated population and the intent-to-treat population, including ESR1 wild type, were announced, and data will be presented at an upcoming scientific meeting.

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Neil M. Iyengar, MD
October 24th 2025
Article

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Dato-DXd May Be Next SOC in First-Line TNBC

Dato-DXd May Be Next SOC in First-Line TNBC

Kristi Rosa
October 20th 2025
Article

Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.


Policies aimed at improving health coverage and financial assistance may help improve treatment affordability to ensure more equitable survival.

Data Show Growing Trend in Insurance/Racial OS Disparities in Breast Cancer

Roman Fabbricatore
October 20th 2025
Article

Policies aimed at improving health coverage and financial assistance may help improve treatment affordability to ensure more equitable survival.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.